Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine

Pediatrics

Volumn 134, Issue 2, 2014, Pages 210-217

  Iroh Tam, Pui Ying ^a   Madoff, Lawrence C ^b,c   Coombes, Brandon ^d   Pelton, Stephen I ^e  

^a University of Minnesota Children's Hospital   (United States)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Children; Comorbidity; Conjugate vaccine; Invasive pneumococcal disease; Severity

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPLENIA; ASTHMA; BACTERIUM ISOLATION; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD DISEASE; CHRONIC LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FEVER; HEALTH SURVEY; HOSPITAL READMISSION; HOSPITALIZED CHILD; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLEURA FLUID; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; SYNOVIAL FLUID; UNITED STATES; VACCINATION;

CHILDREN; COMORBIDITY; CONJUGATE VACCINE; INVASIVE PNEUMOCOCCAL DISEASE; SEVERITY;

CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INFANT; LOGISTIC MODELS; MALE; MASSACHUSETTS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 84905239445     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0473     Document Type: Article

References (30)

1. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008;6(4):288-301 (Pubitemid 351404773)
2. Black RE, Cousens S, Johnson HL, et al Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-1987
3. Rajaratnam JK, Marcus JR, Flaxman AD, et al. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet. 2010;375(9730):1988-2008
4. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). 1997. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/ 00047135.htm. Accessed May 1, 2010
5. Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J. 2010;29(4):289-293
6. Hsu KK, Shea KM, Stevenson AE, Pelton SI; Members of the Massachusetts Department of Public Health. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J. 2011;30(3):251-253
7. US Census Bureau. Age and sex composition: 2010. Available at: www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed April 23, 2013
8. US Census Bureau. QuickFacts from the US Census Bureau. 2011. Available at: http://quickfacts.census.gov/qfd/states/25000.html. Accessed April 23, 2013
9. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage with individual vaccines and selected vaccination series before 24 months of age by state and local area: US National Immunization Survey, Q1/2011-Q4/2011. 2011. Available at: www.cdc.gov/vaccines/stats-surv/nis/tables/ 11/tab09-24mo-iap-2011.pdf. Accessed April 23, 2013
10. Centers for Disease Control and Prevention (CDC). Provisional recommendations for the use of pneumococcal vaccines. Available at: www.cdc.gov/vaccines/recs/provisional/downloads/pneumo-Oct-2008-508.pdf. 2008. Accessed May 2010
11. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis. 2002;35(5):547-555
12. Whitney CG, Farley MM, Hadler J, et al Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343(26):1917-1924 (Pubitemid 32064785)
13. Whitney CG, Farley MM, Hadler J, et al Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746 (Pubitemid 36514704)
14. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≥59 months: selected U.S. regions, 2010-2011. MMWR Morb Mortal Wkly Rep. 2011;60(43):1477-1481
15. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792 (Pubitemid 46658647)
16. Pilishvili T, Lexau C, Farley MM, et al Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41
17. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429-436
18. Feikin DR, Davis M, Nwanyanwu OC, et al. Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr Infect Dis J. 2003;22(6):564-567 (Pubitemid 36782200)
19. Robinson KA, Baughman W, Rothrock G, et al Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729-1735 (Pubitemid 32259907)
20. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772-1778 (Pubitemid 47598445)
21. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Pneumococcal mastoiditis in children and the emergence of multidrugresistant serotype 19A isolates. Pediatrics. 2008;122(1):34-39
22. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42(7):907-914
23. Ampofo K, Pavia AT, Chris S, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J. 2012;31(3):228-234
24. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis. 2014;58(4):517-525
25. Pelton SI. The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses. Clin Infect Dis. 2014;58(4):526-527
26. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J. 2007;26(2):123-128 (Pubitemid 46183361)
27. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14(2):101-107
28. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9):1346-1354 (Pubitemid 351412007)
29. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-182 (Pubitemid 351269154)
30. Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving picture of invasive pneumococcal disease in Massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 2012;31(10):1016-1021